ATE477275T1 - Antikörper gegen cd28 - Google Patents

Antikörper gegen cd28

Info

Publication number
ATE477275T1
ATE477275T1 AT01995797T AT01995797T ATE477275T1 AT E477275 T1 ATE477275 T1 AT E477275T1 AT 01995797 T AT01995797 T AT 01995797T AT 01995797 T AT01995797 T AT 01995797T AT E477275 T1 ATE477275 T1 AT E477275T1
Authority
AT
Austria
Prior art keywords
antibodies against
antibody
receptor
interaction
blocks
Prior art date
Application number
AT01995797T
Other languages
English (en)
Inventor
Jean-Paul Soulillou
Genevieve Laflamme
Bernard Vanhove
Daniel Olive
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE477275T1 publication Critical patent/ATE477275T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01995797T 2000-12-26 2001-12-26 Antikörper gegen cd28 ATE477275T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0017025 2000-12-26
PCT/FR2001/004203 WO2002051871A2 (fr) 2000-12-26 2001-12-26 Anticorps anti-cd28

Publications (1)

Publication Number Publication Date
ATE477275T1 true ATE477275T1 (de) 2010-08-15

Family

ID=8858197

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01995797T ATE477275T1 (de) 2000-12-26 2001-12-26 Antikörper gegen cd28

Country Status (9)

Country Link
US (1) US7723482B2 (de)
EP (1) EP1345969B1 (de)
JP (1) JP4066166B2 (de)
AT (1) ATE477275T1 (de)
DE (1) DE60142794D1 (de)
DK (1) DK1345969T3 (de)
ES (1) ES2353273T3 (de)
PT (1) PT1345969E (de)
WO (1) WO2002051871A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP2363410B1 (de) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
DK2363410T3 (en) * 2003-08-26 2018-01-15 Minerva Biotechnologies Corp ISOFORMER OF MUC1
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
SI2700651T1 (sl) 2008-07-18 2019-08-30 Bristol-Myers Squibb Company Monovalentni sestavki za vezavo CD28 in postopki uporabe
BRPI0920749A8 (pt) 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
EP2210902A1 (de) 2009-01-14 2010-07-28 TcL Pharma Rekombinante monovalente Antikörper
HUE025795T2 (en) * 2009-01-28 2016-05-30 Ind Tech Res Inst Urinary and serum biomarkers linked to diabetic nephropathy
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
PL2536764T3 (pl) 2010-02-18 2018-12-31 Ose Immunotherapeutics Humanizowane przeciwciała anty-CD28
EP2361935A1 (de) * 2010-02-18 2011-08-31 TcL Pharma Humanisierte Anti-CD28-Antikörper
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3091032A1 (de) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Cd3-spezifischer, humanisierter antikörper oder fragment davon
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
KR20180083418A (ko) 2015-11-18 2018-07-20 머크 샤프 앤드 돔 코포레이션 Pd1/ctla4 결합제
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP7691823B2 (ja) 2018-03-15 2025-06-12 ビオンド バイオロジクス リミテッド 可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3104098A1 (en) 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
WO2020047473A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
CN113365663B (zh) 2018-08-30 2025-11-21 免疫生物公司 单链嵌合多肽和其用途
KR20250160211A (ko) 2018-08-30 2025-11-11 이뮤니티바이오, 인크. 다중-사슬 키메라 폴리펩타이드 및 이의 용도
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020070288A1 (en) 2018-10-05 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7685954B2 (ja) 2019-03-14 2025-05-30 ビオンド バイオロジクス リミテッド 低分子脱落遮断剤
EP3962493A2 (de) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Verfahren zur modulation der immunreaktivität/konzentration von irf oder sting oder zur behandlung von krebs mit der verabreichung eines sting-modulators und/oder eines purinergischen rezeptormodulators oder eines postzellularen signalisierungsfaktors
AU2020294797B2 (en) 2019-06-21 2025-12-18 Immunitybio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (de) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Kombination von antikrebstherapien mit induktoren der eisenabhängigen zellulären zerlegung
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
JP2023513573A (ja) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢性および炎症性疾患を治療する方法
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247604A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP7773528B2 (ja) 2020-08-19 2025-11-19 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
EP4363059A1 (de) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Zur förderung der apo-übertragung manipulierte immunzellen und verwendungen davon
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
EP4486368A1 (de) 2022-03-02 2025-01-08 ImmunityBio, Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
EP4507779A1 (de) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Verfahren zur kontrolle der tumorzellabtötung durch licht
EP4598946A1 (de) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Für trif und zusätzliche polypeptide codierende nukleinsäuremoleküle und deren verwendung bei der behandlung von krebs
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2026043906A1 (en) 2024-08-19 2026-02-26 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US20260049118A1 (en) 2024-08-19 2026-02-19 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA91463B (en) * 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
WO1994028912A1 (en) * 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
US5948893A (en) * 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody

Also Published As

Publication number Publication date
PT1345969E (pt) 2010-11-17
EP1345969B1 (de) 2010-08-11
JP4066166B2 (ja) 2008-03-26
WO2002051871A3 (fr) 2002-08-15
US20080038273A1 (en) 2008-02-14
ES2353273T3 (es) 2011-02-28
DK1345969T3 (da) 2010-11-29
JP2004516034A (ja) 2004-06-03
WO2002051871A2 (fr) 2002-07-04
EP1345969A2 (de) 2003-09-24
DE60142794D1 (de) 2010-09-23
US7723482B2 (en) 2010-05-25

Similar Documents

Publication Publication Date Title
ATE477275T1 (de) Antikörper gegen cd28
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE265532T1 (de) Monoklonaler antikörper br110 und dessen anwendung
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DK1047781T3 (da) IL-18-receptorer
EP2345671B8 (de) Optimierte fc varianten und methoden zu ihrer herstellung
NO20041325L (no) Substanser
DE69732868D1 (de) Mittel gegen Juckreiz
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
CY1109536T1 (el) Βελτιωμενες fc πρωτεϊνες συντηξης
TR200003193A3 (tr) Agir hidrokarbon beslemelerin islenmesi için yöntem ve aygit.
ATE225670T1 (de) Antagonistische anti-avb3 integrin antikörper
TW200510459A (en) RG1 antibodies and uses thereof
DE69934241D1 (de) Agonistische antikörper gegen tie2
PT1519748E (pt) Micropartículas com anticorpos monoclonais específicos de cd28
TR200001313T2 (tr) Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri
ES2193102T3 (es) Compuestos de imidocromo en sistemas catalizadores para la polimerizacion de olefinas.
ATE286073T1 (de) Antikörper gegen spaltprodukte von vimentin
BR0015872A (pt) Agentes antitrombóticos
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
SE9604581D0 (sv) An agent against cancer and virus infections
TR199903187A3 (tr) Kadife kumaslarin yüz-yüze dokunmasi için yöntem.
ITGE940069A0 (it) Dispositivo formatore-trasferitore di file di pacchetti, in particolare di pacchetti di sigarette, o simili.
ATE285789T1 (de) Mukosale zytotoxische t-lymphozytenantwort

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1345969

Country of ref document: EP